Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET
Company Participants
Todd Tushla - VP, IR
Kevin Gorman - CEO & Director
Matthew Abernethy - CFO
Eric Benevich - Chief Commercial Officer
Eiry Roberts - Chief Medical Officer
Kyle Gano - Chief Business Development and Strategy Officer
Conference Call Participants
Paul Matteis - Stifel, Nicolaus & Company
Brian Skorney - Robert W. Baird & Co.
Carter Gould - Barclays Bank
Neena Bitritto-Garg - Citigroup
Tazeen Ahmad - Bank of America Merrill Lynch
Joshua Schimmer - Evercore ISI
Anupam Rama - JPMorgan Chase & Co.
Charles Duncan - Cantor Fitzgerald & Co.
Philip Nadeau - Cowen and Company
Jeff Hung - Morgan Stanley
Chris Shibutani - Goldman Sachs Group
Jay Olson - Oppenheimer
Laura Chico - Wedbush Securities
Marc Goodman - SVB Leerink
Vamil Divan - Mizuho Securities
Myles Minter - William Blair & Company
Yatin Suneja - Guggenheim Securities
Operator
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports First Quarter Results. [Operator Instructions].
It is now my pleasure to turn today's program over to Todd Tushla, VP of Investor Relations.
Todd Tushla
Thank you, operator. Good morning, everyone, and thanks for joining our first quarter 2022 earnings call. With me as usual are Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Amy Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.
Before we get going, I'll remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After our prepared remarks, we'll be happy to address your questions. Now I'll hand the call over to Kevin Gorman.
Kevin Gorman
Thank you, Todd. Good morning, everyone. I'm sure you saw our press release this morning, and I have to say I'm very pleased with the work of our entire commercial and medical organizations in educating health care professionals on TD resulted in a record number of TD sufferers being treated with INGREZZA last quarter.
Now while the external environment has improved, it is not back to normal, and there are still challenges. However, I believe we are adapting well to the remote delivery of health care, which we know will persist at some level moving forward. So we have now seen our fourth consecutive quarter of sequential growth.